Objectives As the bioavailability of erlotinib is dependent on gastric pH, an increase in
gastric pH via the concurrent use of gastric acid suppressive medications (AS) may reduce …

Purpose: Erlotinib and gefitinib are both tyrosine kinase inhibitors (TKIs) approved for the
treatment of non-small cell lung cancer (NSCLC). Although it is well known that the increase …

Background Gastric acid-suppressing medications (AS), namely, proton pump inhibitors and
histamine-2 receptor antagonists, increase gastric pH, which may reduce the absorption of …

Background Erlotinib is a key therapy for advanced NSCLC. Concurrent AS therapy with
TKIs might reduce TKI plasma levels. Because of gastroesophageal reflux disease …

Background Erlotinib and gefitinib are weak base drugs whose absorption and clinical
efficacy may be impaired by concomitant gastric acid suppressive (AS) therapy, yet proton …

Background: Erlotinib is used for treating non–small cell lung cancer (NSCLC). Intestinal
absorption of erlotinib is impaired under gastric pH elevation; therefore, coadministration of …

The aim of this study was to evaluate the effect of coadministration of acid-reducing agents
on the pharmacokinetic exposure of orally administered epidermal growth factor receptor …

Purpose Acid-suppression therapy is known to decrease the systemic exposure of erlotinib.
The erlotinib prescribing information recommends staggering dosing with a histamine-2 …

Context. Erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, exhibits a
drug interaction with proton pump inhibitors (PPIs) and histamine-2 receptor antagonists …

Purpose Erlotinib depends on stomach pH for its bioavailability. When erlotinib is taken
concurrently with a proton pump inhibitor (PPI), stomach pH increases, which results in a …